What Cytocares does

Cytocares (惠和生物技术（上海）有限公司) is a Shanghai-based, privately-held clinical-stage biopharmaceutical company founded in December 2015 (originally as Shanghai Nearshore Biotechnology, renamed in February 2021). The company focuses on designing and developing multi-specific antibody drugs — specifically trispecific antibodies — for tumor immunotherapy and, more recently, autoimmune disease. Cytocares operates three proprietary platforms: TriTETM (a trispecific T-cell engager employing the CD3/CD28 'Two-Signal' co-stimulation mechanism), CCNKTM (an NK-cell engager leveraging IL15 and NKG2D pathways), and CCMphiTM (a macrophage-engager platform targeting tumor-associated macrophage reprogramming and 'don't eat me' signal blockade).

The lead asset CC312 is a first-in-class anti-CD19×CD3×CD28 trispecific antibody developed from the TriTETM platform. It has received FDA IND clearance (May 2022, first in China and third globally in its class), NMPA IND approval (March 2023) for relapsed/refractory CD19+ B-cell malignancies, and a subsequent CDE IND approval (August 2024) for systemic lupus erythematosus (SLE). The company is conducting multi-center Phase I clinical trials at leading Chinese hospitals including the Chinese Academy of Medical Sciences Blood Disease Hospital, Henan Cancer Hospital, and Zhujiang Hospital, with dose escalation through the 6th cohort and early data showing approximately 90% B-cell depletion at low doses and a favorable safety profile. CC312 is positioned by the company as an 'antibody version of CAR-T' offering the efficacy of cell therapy with the manufacturing convenience, lower cost, and broader patient accessibility of an off-the-shelf biologic.

Cytocares is pre-commercial and currently generates no product revenue; its business model is built around drug development with the expectation of future commercialization and/or out-licensing of pipeline assets. The company has raised approximately 100 million RMB (~$14.4M) in a May 2023 Series A+ round led by Shenzhen Capital Group and Prosperico Ventures, with Jingxu Ventures, Tailong Investments, Jinyu Maowu, and Baisai Gene participating. GTM activities are concentrated on clinical trial execution, BD/partnering outreach, scientific conference presence, and academic engagement rather than commercial sales. Manufacturing is outsourced to CDMO partner MabPlex. The company is led by CEO Yingfeng Huang (appointed June 2023) and COO Zeng Li (appointed February 2022), with scientific founders from Fudan University and the Chinese University of Hong Kong.

Name

Cytocares

Legal name

惠和生物技术（上海）有限公司

Website

https://cytocares.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Cytocares (惠和生物技术) is a Shanghai-based, clinical-stage biotech developing trispecific antibody drugs for cancer immunotherapy and autoimmune disease. Its lead asset CC312, an anti-CD19×CD3×CD28 T-cell engager, is in multi-center Phase I trials for B-cell malignancies and SLE.

Ownership category

akta.pro rank

Product category

Immuno-oncology Biologics / Trispecific Antibody Drugs

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Trispecific antibody drugs
• Immuno-oncology biologics
• Multi-specific antibody platforms
• Tumor immunotherapy
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Biopharmaceutical Drug Development & Commercialization: CytoCares is a pre-commercial biotech company developing novel trispecific antibody drugs. The company has no marketed products yet and generates no product revenue. Revenue will come from drug commercialization and/or licensing/out-licensing deals upon successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cytocares designs and develops trispecific antibody drugs for tumor immunotherapy using three proprietary platforms (TriTETM, CCNKTM, CCMφTM) that engage T cells, NK cells, or macrophages to kill cancer cells. Its lead clinical asset CC312, a CD19×CD3×CD28 trispecific antibody, is in Phase I clinical trials in China for relapsed/refractory B-cell malignancies and systemic lupus erythematosus (SLE), with both FDA and NMPA IND approvals secured. The company currently has no marketed products and operates as a clinical-stage biotech pursuing licensing and partnership opportunities.

Product overview

Cytocares (惠和生物技术（上海）有限公司) is an immuno-oncology focused biotech company developing multi-specific antibody drugs. The company operates three proprietary technology platforms: TriTETM (T-cell Engager), CCNKTM (NK cell engager), and CCMφTM (Macrophage engager). The lead product CC312 is a trispecific antibody targeting CD19/CD3/CD28, representing the company's first-in-class innovation. The platforms enable development of antibodies that bridge immune cells (T cells, NK cells, or macrophages) with tumor cells, providing sustained immune activation compared to conventional bispecific antibodies or CAR-T therapies. The company is expanding from hematologic malignancies to solid tumors and autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Brands

• TriTETM Platform: Trispecific T-cell Engager (TriTE) platform employing CD3/CD28 dual-signal activation mechanism for T cell engagement and durable immune response against cancer cells.
• CCNKTM Platform
• CCMφTM Platform

Products and services

• TriTETM Platform

Quantifiable outcome

• 90% B-cell depletion observed at low doses in CC312 Phase I clinical trials with good safety and tolerability
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered strategic and core.

• 迈百瑞 (MabPlex)strategicImplementation/ SI/ Consulting PartnerStrategic CMC partner for CytoCares, providing one-stop biologics CDMO services including cell line development, process development, clinical sample production, and quality management for CC312. MabPlex is a global CDMO with 76 comprehensive projects承接, 30 of which have received IND approvals.
• 中国医学科学院血液病医院 (Chinese Academy of Medical Sciences Blood Disease Hospital)coreStrategic or Co-development PartnerPrimary clinical trial site for CC312 Phase I study. Conducting multi-center Phase I clinical trial evaluating CC312 safety, tolerability, PK, PD, immunogenicity and preliminary anti-tumor activity in relapsed/refractory CD19+ B-cell hematologic malignancies. Study initiated July 2023 with first patient dosed August 2023.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• BeiGene: Leading China-headquartered oncology biotech with tislelizumab and hematology franchise; broader portfolio but the most relevant China-listed comp for clinical-stage oncology valuation benchmarks.
• Genmab: Pioneer of the DuoBody bispecific platform with approved products (epcoritamab via AbbVie, glofitamab via Roche) in B-cell malignancies; sets the standard for CD3-based T-cell engager pharmacology that Cytocares' CC312 is differentiated against.

Direct peers

• Elpiscience Biopharma: Shanghai-based clinical-stage immuno-oncology biotech developing bispecific and multi-specific antibodies in hematologic and solid tumors; comparable scale, stage, and tri-specific-like targeting strategy to Cytocares.
• Xencor: U.S.-based biotech whose XmAb bispecific platform and pipeline (including CD19×CD3 engagers in oncology and autoimmune) closely parallels Cytocares' trispecific T-cell engager approach.
• MacroGenics: U.S. biotech with the DART and TRIDENT platforms for bispecific/trispecific antibody drug development in oncology, including B-cell hematologic malignancy programs; a comparable multi-specific T-cell engager developer.
• Cullinan Oncology: Clinical-stage biotech developing trispecific T-cell engagers (e.g., CLN-978) with similar CD19-targeted immunology focus; a U.S. comp with overlapping multi-specific antibody technology and B-cell indication strategy.
• Akeso Biopharma: Akeso is a Chinese biotech with a leading bispecific antibody pipeline (e.g., ivonescimab/cadonilimab), a shared multi-specific antibody development thesis, and overlapping immuno-oncology focus — a direct comp for Cytocares' trispecific T-cell engager approach.
• Maverick Therapeutics (Takeda): Developed COBRA-derived T-cell engagers including CD3×CD28 conditional trispecific formats that directly mirror CC312's CD3+CD28 architecture; was acquired by Takeda in 2021 for ~$525M, setting a relevant M&A comp.

Regional players

• Shanghai Henlius Biotech: China-based biopharmaceutical company developing monoclonal and bispecific antibodies including tri-specific candidates in oncology; a regional peer with shared therapeutic focus and Chinese clinical trial infrastructure.
• Harbour BioMed: Hong Kong- and Boston-based biotech developing bispecific antibodies (e.g., batoclimab) with a heavy China/Asia clinical footprint; comparable in stage, therapeutic area, and bispecific/trispecific ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytocares